Amgen's Q3 earnings call revealed a mixed picture, with the company reiterating its full-year revenue guidance and expecting a modest impact from the bundling of dialysis services. The launch of Prolia, a new osteoporosis treatment, is progressing steadily, although reimbursement issues are causing some delays. Management expressed confidence in the product's long-term potential and anticipated increased adoption as reimbursement processes become more streamlined. 

[1]